MedTrace Logo

Levetiracetam and Memory Function in Amnestic Mild Cognitive Impairment (MCI)

NCT01044758 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 96

Last updated 2017-08-21

Study results available
· View outcomes & findings →

Summary

This research is being done to find out if daily use of the drug levetiracetam can improve memory function in individuals with memory problems like those associated with Mild Cognitive Impairment (MCI) and Alzheimer's disease (AD).

Conditions

  • Mild Cognitive Impairment (MCI)

Interventions

DRUG

Levetiracetam 62.5mg

62.5mg twice daily (2 weeks)

DRUG

Levetiracetam 125mg

125mg twice daily (2 weeks)

DRUG

Levetiracetam 250mg

250mg twice daily (2 weeks)

DRUG

Placebo

placebo capsule twice daily (2 weeks)

Sponsors & Collaborators

Principal Investigators

  • Gregory L Krauss, MD · Johns Hopkins University

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
50 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-12-31
Primary Completion
2012-07-31
Completion
2012-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01044758 on ClinicalTrials.gov